It is our pleasure to announce that LIDSEN has joined the ORCID community. ORCID (Open Researcher and Contributor ID), a global, not-for-profit organization, provides a free, unique, and persistent digital identifier (an ORCID iD), which can automatically link researchers to their own contributions, so as to disambiguate researchers from one another. Authors who publish with OBM Neurobiology are greatly encouraged to register for a unique iD to ensure proper attribution.

We sincerely welcome Prof. Dr. Najam Sharif, from Global Alliance and External Research, Santen Inc., USA, to join the Editorial Board of OBM Neurobiology. Dr. Sharif, PhD, DSc has >34-years’ pharmaceutical drug discovery research/development experience covering neuroscience and ophthalmology. His 22-year tenure at Alcon resulted in his contributions to the discovery, characterization, development and US FDA approvals of Patanol®/Pataday®/Pazeo® and Emadine® to treat allergic conjunctivitis, and Travatan® and Simbrinza® for the treatment of ocular hypertension / Glaucoma. Currently, he is Vice President, Global Alliances and External Research, Ophthalmology Innovation Center at Santen Inc USA, where he has been instrumental in establishing, nurturing and managing long term partnerships with pharma companies and several global universities. Dr. Sharif serves on numerous committees of many learned Societies (including ISER, elected Trustee of AOPT & Gold Fellow; Gold Fellow of ARVO and Fellow of British Pharmacological Society (BPS)). Dr. Sharif is Editor/Associate Editor/Editorial Board member of many Pharmacology and Ophthalmic journals. He is the recipient of the inaugural Dr. Roger Vogel award for ocular pharmaceutical research (ARVO Foundation, 2104), the recipient of the “Sir James Black Award” for contributions to drug discovery (BPS, 2017), and awardee of the Ernst Barany Prize for outstanding contributions to ocular pharmacology. Dr. Sharif is an Adjunct Professor / Honorary Senior Lecturer / Senior Principal Investigator and graduate Faculty at multiple Universities worldwide. He has also been a PhD-candidates’ supervisor, advisor and mentor to several students at numerous academic institutions. Dr. Sharif has published >215 scientific articles, edited 3 books, holds 24 issued US/EU patents, and has filed >30 patent applications over the last two decades.We appreciate Dr. Sharif for his participation and support.

We sincerely welcome Dr. Thomas H.J. Burne, from University of Queensland, Australia, to join the Editorial Board of OBM Neurobiology. Dr. Burne has abundant professional experience in neuropsychiatric diseases, animal models, biological psychiatry, neuroanatomy, molecular biology, schizophrenia, behavioural neuroscience, et al. We appreciate Dr. Burne for his participation and support.

We sincerely welcome Dr. Khue Vu Nguyen, from University of California, USA, to join the Editorial Board of OBM Neurobiology. Dr. Nguyen has abundant professional experience in molecular biology, genetic diseases, enzymology, biosensors, biopolymers, neurodevelopmental and neurodegenerative disorders, cancer, etc. We appreciate Dr. Nguyen for his participation and support.

We sincerely welcome Dr. Jasmin from University of California San Francisco, United States, to join the Editorial Board of OBM Neurobiology. Dr. Jasmin has extensive experience in: pain, stress, theentericnervous system, primary sensory neurons, dorsal root ganglion, pharmacology, GABA, glutamate, TRPM8, and health care economics and policies, etc. We are sincerely grateful to Dr. Jasmin for his participation and support.

We sincerely welcome Dr. Khan from University of Tennessee Health Science Center, United States, to join the Editorial Board of OBM Neurobiology. Dr. Khan has extensive experience in: neuroscience, pharmacology, neurodegeneration, neuroinflammation, Parkinson’s disease, stroke; Alzheimer’s disease, multiple sclerosis and traumatic brain injury, etc. We are sincerely grateful to Dr. Khan for his participation and support.

We sincerely welcome Dr. Sabine M. Hölter, from Helmholtz Zentrum München and Technical University Munich, Germany, to join the Editorial Board of OBM Neurobiology. Dr. Hölter has abundant professional experience in behavioral neuroscience, neuropsychiatric diseases, neurodegeneration, molecular neurogenetics, mouse phenotyping, neuropharmacology, neurobiology and brain physiology, etc. We appreciate Dr. Hölter for her participation and support.

We sincerely welcome Dr. Viscomi from IRCCS Fondazione Santa Lucia, Italy, to join the Editorial Board of OBM Neurobiology. Dr. Viscomi has extensive experience in: neurodegenerative disease, brain injury, neuroscience biochemistry, etc. We are sincerely grateful to Dr. Viscomi for her participation and support.

We sincerely welcome Professor Reale, from “G.d’Annunzio” University, Italy, to join the Editorial Board of OBM Neurobiology. Professor Reale has abundant professional experience in inflammation, cytokines, neurodegenerative disease, neuroinflammation, autoimmune diseases, probiotics and inflammation, etc. We appreciate Professor Reale for her participation and support.

We sincerely welcome Professor Campolongo from Universita degli Studi di Roma La Sapienza, Italy, to join the Editorial Board of OBM Neurobiology. Professor Campolongo has extensive experience in: neurobiology, neuropsychopharmacology, behavioral neuroscience, neuropharmacology, behavioral testing, behavioral pharmacology, cannabinoid research, etc. We are sincerely grateful to Professor Campolongo for her participation and support.